High‐dose vs low‐dose colchicine
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
Findings
What do systematic reviews say?
96 questions · 96 findings · 7 reviews · Headline outcomes only
No studies found 35 · 36.5%GRADE not reported 6 · 6.3%Very low 13 · 13.5%Low 20 · 20.8%Moderate 22 · 22.9%High 0 · 0%
Canakinumab vs placebo
Number of participants experiencing an attacka · people with colchicine‐resistant familial Mediterranean fever
Canakinumab probably leads to lower number of participants experiencing an attacka compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyRR 0.41 [0.26, 0.65]1 study · 63 participantsModerate
Canakinumab vs placebo
Duration of attacks · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Canakinumab vs placebo
Time between attacks · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Canakinumab vs placebo
Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Canakinumab vs placebo
Adverse drug reactions · people with colchicine‐resistant familial Mediterranean fever
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 63 participantsModerate
Canakinumab vs placebo
Acute‐phase response · people with colchicine‐resistant familial Mediterranean fever
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 63 participantsModerate
Intervention not reported
months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)
The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).
1 finding from 1 review
- RR 0.41 [0.28, 0.61]2 studies · 360 participantsModerate
Intervention not reported
Symptom relief at 72 hours Patient reported
The intervention may leads to higher symptom relief at 72 hours Patient reported (low certainty).
1 finding from 1 review
- RR 1.4 [1.26, 1.56]4 studies · 564 participantsLow
Intervention not reported
Total adverse effects Patient reported
The intervention showed no clear difference in total adverse effects Patient reported (low certainty).
1 finding from 1 review
- RR 1.26 [0.75, 2.12]4 studies · 564 participantsLow
Intervention not reported
Adverse effects necessitating stop of therapy Patient reported
The intervention probably leads to higher adverse effects necessitating stop of therapy Patient reported (moderate certainty).
1 finding from 1 review
- RR 1.87 [1.02, 3.41]4 studies · 564 participantsModerate
Intervention not reported
months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)
The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).
1 finding from 1 review
- RR 0.28 [0.17, 0.47]2 studies · 204 participantsModerate
Intervention not reported
months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)
The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).
1 finding from 1 review
- RR 0.36 [0.23, 0.56]2 studies · 204 participantsModerate
Intervention not reported
months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)
The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).
1 finding from 1 review
- RR 0.38 [0.25, 0.58]2 studies · 204 participantsModerate
Intervention not reported
months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)
The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).
1 finding from 1 review
- RR 0.36 [0.23, 0.58]2 studies · 360 participantsModerate
Intervention not reported
months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)
The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).
1 finding from 1 review
- RR 0.4 [0.26, 0.61]2 studies · 360 participantsModerate